Kromatid, a pioneer in genomic structural analysis, has successfully raised $8,000,000 in Series C funding, led by BroadOak Capital Partners and other investors. This new round will allow Kromatid to accelerate adoption of its proprietary Directional Genomic Hybridization (dGH™) technology, which offers unparalleled precision in detecting structural variations and validating engineered cell lines.

Who Is Kromatid?

Founded by Jim Chomas, Kromatid provides advanced genomic tools that are increasingly indispensable for cell and gene therapy, oncology research, and cytogenetic testing. Its dGH™ technology allows researchers and biopharma companies to visualize and validate genomic changes with unmatched resolution - making it possible to spot rearrangements or anomalies that traditional methods like FISH often miss.

By delivering greater accuracy and speed, Kromatid helps therapeutic developers de-risk their pipelines, streamline regulatory submissions, and build confidence in the integrity of their engineered cell lines.

Why Genomic Structural Analysis Matters Now

The global genomics market was valued at $28.1 billion in 2022 and is forecast to reach $94.7 billion by 2030, growing at a 16.5% CAGR. Within that, structural variation detection plays an increasingly vital role, especially as cell and gene therapies scale toward what analysts project to be a $35 billion market by 2030. Oncology alone accounts for another $15 billion opportunity by 2030, with precision testing and structural validation forming the backbone of new treatment development.

But here’s the deeper founder insight that hides in these numbers: the most durable companies aren’t always the ones developing the therapies themselves - they’re the ones that provide the enabling infrastructure. Drug developers can rise and fall based on the success of a single clinical trial, but the companies that sell the “picks and shovels” of innovation - like Kromatid with its genomic validation tools - benefit from every trial, every lab, and every therapy in motion. Stripe did this with payments. Datadog did it with cloud observability. And Kromatid is doing it in genomics. For founders, the lesson is clear: sometimes the most transformative play is not to chase the spotlight, but to make yourself the backbone everyone else depends on.

How Kromatid Will Use the $8M

With this Series C funding, Kromatid will:

• Scale commercial operations to meet demand from biopharma clients worldwide.
  
• Advance dGH™ technology, pushing automation and resolution for faster results.
  
• Support cell and gene therapy developers, ensuring genomic structural integrity for regulatory approvals.
  
• Expand its scientific team, deepening expertise to tackle more complex applications in oncology and rare disease research.
  

This balanced approach - product innovation paired with global reach - strengthens Kromatid’s position as an essential partner across the genomic research and clinical development pipeline.

Investor Confidence

The support of BroadOak Capital Partners, with its specialization in life sciences tools and diagnostics, provides Kromatid with more than just capital. BroadOak’s network and experience scaling biotech infrastructure companies offer Kromatid strategic advantages in capturing a larger share of the genomic analysis market.

Market Outlook for Genomic Structural Testing

The momentum behind genomic analysis is undeniable:

• The cytogenetics market was valued at $2.6 billion in 2022 and is growing at over 10% CAGR through 2030.
  
• The genome editing tools market is expected to hit $21 billion by 2030, with validation technologies like dGH™ considered mission-critical.
  
• Regulatory bodies like the FDA and EMA increasingly demand high-confidence genomic integrity testing before therapy approvals.
  

These trends make structural analysis not just important, but essential - and they place Kromatid’s offerings squarely in the middle of a multi-billion-dollar ecosystem.

Competitive Advantage

Kromatid stands out because of:

• Proprietary dGH™ technology with higher accuracy than traditional FISH.
  
• Faster turnaround times, cutting analysis from weeks to days.
  
• Regulatory alignment, providing trusted results for therapy submissions.
  
• Cross-sector applicability, serving oncology, rare diseases, and cell and gene therapy alike.
  

This positioning means Kromatid isn’t betting on one vertical - it’s embedding itself into the workflows of an entire industry.

What’s Next for Kromatid

Armed with fresh capital, Kromatid will continue to expand internationally, integrate automation and AI-driven analytics, and position itself as the gold standard for genomic structural validation. As the genomics market nears $100 billion, the role of trusted infrastructure providers like Kromatid will only grow.

By selling the essential tools that power innovation, Kromatid is ensuring that no matter which therapies succeed, its place in the future of precision medicine is secure.

---